Hospitals & Clinics: market research reports

... Portugal has already made considerable savings in the healthcaresectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients,changes to reference pricing, reductions in pharmacy margins and price cuts just some of ...  |  more...

... are a small improvement, though definitely not what producerswould have wanted ideally. With part of the objective of the claw-back tax to improve the timeliness ofpayments for reimbursed medicines, which has been a major difficulty ...  |  more...

... by both NGOs and international investors as a sign that Zambia istaking its commitment to healthcare seriously. The country suffers from a burden of both communicableand non-communicable diseases, with a high incidence of HIV and ...  |  more...

... and pharmaceutical industry to reduce thefinancial burden of diseases, and the country's private healthcare sectors provide opportunities forforeign companies. However, the increasing drug rebate level has significantly undermined the profitsrecorded by generic drugmakers. The more ...  |  more...

... opportunities forgeneric drugmakers from neighbouring Latin American countries and India. We highlight that Costa Ricaand Panama can be the premier countries in the region for foreign drugmakers to expand their presence. Headline Expenditure Projections Pharmaceuticals: ...  |  more...

... generic medicines, in tandem withprice-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake ofgeneric medicines will conspire to keep longer term growth steady, boosted by upward volume changes,with the patented drug market ...  |  more...

... support and pharmaceutical trade. It also covers the market trends and outlook, regulatory changes, counterfeit drugs, industry SWOT analysis and market outlook, plus profile, comparative matrix and SWOT analysis of the leading players: PT Kalbe ...  |  more...

... believes the government needs to do more to alter patients' attitudestowards these drugs as this is the main growth deterrent. Headline Expenditure Projections Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% declinein ...  |  more...

... non-oil economies. Political risk remains elevated as many disputesbetween them are still unresolved. These macroeconomic uncertainties will mean lack of focus on publichealthcare provision, which further complicates the problem that the general population are unable ...  |  more...

... and the vast majority of expenditure will be on low-marginessential medicines. Due to tepid economic growth, our outlook for Gabon's pharmaceutical market isbelow that expected to be posted by many of its sub-Saharan Africa neighbours. ...  |  more...

... an analysis of the healthcare, regulatory and reimbursement landscape of Jordan. The report identifies the key trends in the healthcare market of Jordan. The report also provides insights on the demographic, regulatory, reimbursement landscape and ...  |  more...

... volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure rates (firms, establishments, small business, startups). startup activity rates ...  |  more...

... volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure rates (firms, establishments, small business, startups). startup activity rates ...  |  more...